Our Recommendations
- Clinical management of COVID-19: living guideline, 23 June 2022 (Arabic) (2022)
- Manejo clínico de la COVID-19: orientaciones evolutivas, 23 de junio de 2022 (2022)
- Protocolo de Manejo Clínico para o Novo Coronavírus (2019-nCoV) (2020)
- Manuel de prévention et de traitement du COVID-19 (2020)
- Covid-19 AMBOSS (2020)
New Publications
- Therapeutics and COVID-19 (Living Guideline, 10 November 2023) (2023)
- Clinical management of COVID-19: Living guideline, 18 August 2023 (2023)
- Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 13 January 2023 (2023)
- Clinical management of COVID-19: living guideline, 13 January 2023 (2023)
- Manejo clínico de la COVID-19, 14 de septiembre de 2022 (2022)
Filter
220
Featured
Recommendations
67
Language
Document type
Guidelines
123
Fact sheets
42
Manuals
23
Studies & Reports
8
Online Courses
7
Infographics
6
Situation Updates
5
Training Material
2
Resource Platforms
2
Videos
2
Countries / Regions
Russia
30
Brazil
23
Latin America and the Carribbean
14
Germany
11
Mozambique
8
West and Central Africa
8
Middle East and North Africa
8
Angola
8
Eastern Europe and Central Asia
7
Guinea-Bissau
6
Spain
6
Global
5
Ecuador
5
Syria
4
Africa
4
South Africa
4
Yemen
4
France
3
East and Southern Africa
3
Eastern Europe
3
India
3
Portugal
2
Vietnam
2
Sudan
2
Switzerland
1
Ukraine
1
Turkey
1
Benin
1
Togo
1
Cameroon
1
Nigeria
1
Canada
1
Senegal
1
Congo-Brazzaville
1
Niger
1
Burkina Faso
1
Burundi
1
Austria
1
Philippines
1
Italy
1
Haiti
1
Saudi Arabia
1
South–East Asia Region
1
Western Pacific Region
1
Western and Central Europe
1
Luxembourg
1
Belgium
1
United Kingdom
1
Côte d’Ivoire / Ivory Coast
1
Bolivia
1
Djibouti
1
Mali
1
Chad
1
Madagascar
1
Authors & Publishers
Publication Years
Category
Countries
117
Clinical Guidelines
18
Women & Child Health
9
Capacity Building
4
Key Resources
1
Pharmacy & Technologies
1
22 July 2022. This document provides the case definitions for public health surveillance of COVID-19 in humans caused by SARS-COV-2 infection.
List of essential medicines for the management of patients admitted in intensive care units with a suspected or confirmed diagnosis of COVID 19. Third version, 1 February 2022
Updated 2022. This guide addresses the care pathway from presentation of the patient to a health facility to patient discharge. It considers different levels of disease severity, from asymptomatic individuals to critically ill patients. Accounting for variations in the benefits and harms of chest im...
For patients on NIPPV or HFNO with persistent hypoxaemia or respiratory distress:
• Check the equipment: inspect the exterior of the machine, the tubing (circuit), the mask for any sign of mechanical damage, confirm it fits securely without leak (if CPAP/BiPAP) and the filters are in place. Ensur...
Molnupiravir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Update, 23 de junio de 2022
First published in 2020, this toolkit is intended for clinicians working in acute care, managing adult and paediatric patients with acute respiratory infection, including severe pneumonia, acute respiratory distress syndrome, sepsis and septic shock. The main objective is to provide key tools for us...
The World Health Organization (WHO) recognizes the challenges countries face for maintaining their COVID-19 response while addressing competing public health challenges, conflicts, climate change and economic crises. WHO continues to support countries in adjusting COVID-19 strategies to reflect succ...
May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,...
Nirmatrelvir-ritonavir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Updated Treatment Guidelines
Administration of Remdesivir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi...
Remdesivir for COVID-19
recommended
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
Ongoing Living Update of COVID-19 Therapeutic Options: Summary of Evidence, Rapid Review 22 February 2022
recommended
This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. In recognition of the fact that there are numerous ongoing clinical studies, PAHO will periodically up...
Poster, 4 Janaury 2022
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
